BioSpace News Archive

(“IR-MED or the “Company”) (OTCQB:IRME), an innovative medical device company, developing non-invasive, real-time detection devices that utilize Infra-Red light spectroscopy (IR) and Artificial Intelligence (AR) for use by healthcare professionals, has announced that its wholly-owned subsidiary IR-Med Ltd. has submitted a new provisional patent application covering new methods relating to its non-invasive device, PressureSafe, for detecting and classifying early-stage pressure injuries (PI).

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), today announced financial results for the quarter ended June 30, 2022, and provided an update on its clinical programs.

Hospital for Special Surgery, the academic medical center specialized in musculoskeletal care since 1863, announced the appointment of Sheeraz Qureshi, MD, MBA as co-chief of HSS Spine, effective October 1, 2022.

Amid signs that a more severe influenza season is approaching in the US, a panel of public health leaders urged that people get vaccinated in preparation for the upcoming influenza season and warned that patients in high-risk populations tend to suffer significant flu-related health disparities.3

Wilmington, Delaware, United States, Transparency Market Research Inc. – Blood transfusion diagnostics are products used to conduct tests before transfusion of blood and blood products from donor to recipient.

The rising cases of infectious diseases and various types of chronic diseases such as cancer are projected to add boost to the overall rapid microbiology testing market.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2022 and provided a business update.

PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc., announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.